Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
grabbed some down here, down from over 7 when the PR came out , if you have patience this will be a good one https://finance.yahoo.com/news/coeptis-therapeutics-inc-bull-horn-110000488.html
$COEP Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger AgreementPress Release | 04/19/2022
Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement
PR Newswire
WEXFORD, Pa., and MIAMI, Fla., April 19, 2022
Transaction expected to accelerate Coeptis' ability to progress its innovative cell therapy platforms for cancer
David Mehalick of Coeptis to serve as Chief Executive Officer;
Chris Calise of Bull Horn to join the Board of Directors
Merger anticipated to close in third quarter 2022; combined company anticipated to list on Nasdaq
WEXFORD, Pa., and MIAMI, Fla., April 19, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, and Bull Horn Holdings Corp. (Nasdaq: BHSE) ("Bull Horn"), a special purpose acquisition company (SPAC), today announced they have entered into a definitive merger agreement for a business combination that will result in Coeptis becoming a wholly-owned subsidiary of Bull Horn. Under the terms of the merger agreement, a wholly-owned subsidiary of Bull Horn will merge with and into Coeptis and the holders of the outstanding Coeptis shares will receive equity in Bull Horn valued at $175 million (subject to adjustments). The Boards of Directors of both Coeptis and Bull Horn have unanimously approved the proposed merger, which is subject to customary closing conditions, including receipt of all regulatory approvals, as well as the approval of the proposed merger by Coeptis' and Bull Horn's shareholders. The close of the transaction is anticipated to occur in the third quarter 2022, with Bull Horn to domesticate from the British Virgin Islands to a Delaware corporation prior to the closing. Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings, Inc. and is expected to list on Nasdaq under the ticker symbol "COEP." Coeptis Therapeutics' current President and Chief Executive Officer, David Mehalick, will lead the combined company as President and Chief Executive Officer, and current Chief Financial Officer of Bull Horn, Chris Calise, will join the post-closing Board of Directors.
Coeptis Therapeutics logo
Coeptis is a developer of cell therapy platforms for cancer with the potential to disrupt conventional treatment paradigms and improve clinical outcomes. Coeptis' product portfolio is highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is co-developing with VyGen-Bio, Inc. CD38-GEAR-NK is a natural killer (NK) cell-based investigational therapeutic engineered to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). CD38-Diagnostic is a pre-clinical in vitro screening tool to potentially pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as a monotherapy or in combination with CD38-GEAR-NK.
"Today's announcement is a key milestone for Coeptis as it gains access to the capital needed to advance our product portfolio highlighted by CD38-GEAR-NK and CD38-Diagnostic," said Mr. Mehalick. "The combination of CD38-GEAR-NK and CD38-Diagnostic has the potential to provide a more targeted administration of anti-CD38 mAbs in the treatment of cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. I would like to thank all those involved in achieving this milestone, including Bull Horn, Bridgeway Capital Partners, our existing and new investors, and the entire Coeptis team."
"We are thrilled to have the opportunity to impact the advancement of technology and assets that will benefit cancer patients through this combination with Coeptis. Led by an exceptional management team, Coeptis is taking a novel approach to treating patients with cancer and expanding its development pipeline," said Mr. Calise. "We are excited by Coeptis' plans for the technology, and view this opportunity as a significant value driver for our shareholders."
The transaction is subject to closing conditions, including the approval of holders of a majority of the outstanding shares of Coeptis voting stock and Bull Horn ordinary shares, and other customary conditions. Bridgeway Capital Partners and Meister Seelig & Fein LLP served as financial and legal advisors, respectively, to Coeptis. Jones Trading and Ellenoff Grossman & Schole LLP served as financial and legal advisors, respectively, to Bull Horn.
Additional information about the transaction will be provided in a Current Report on Form 8-K to be filed by Bull Horn Holdings Corp. and Coeptis Therapeutics, Inc. with the Securities and Exchange Commission ("SEC") and will be available at the SEC's website, www.sec.gov.
About Coeptis Therapeutics, Inc.
Coeptis Therapeutics, Inc., along with its wholly owned subsidiary Coeptis Pharmaceuticals, Inc. (together "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. Coeptis was founded in 2017 and is headquartered in Wexford, Pa.
About Bull Horn Holdings Corp.
Bull Horn Holdings Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting an initial business combination. Since its initial public offering, Bull Horn has focused its search for an initial business combination on businesses that may provide significant opportunities for attractive investor returns.
Additional Information and Where to Find It
In connection with the merger agreement and the proposed business combination, Bull Horn intends to file with the SEC a Registration Statement, which will include a preliminary proxy statement/prospectus and a proxy statement/prospectus. Bull Horn's stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and documents incorporated by reference therein filed in connection with the business combination, as these materials will contain important information about Bull Horn, Coeptis, the merger agreement and the business combination. When available, the definitive proxy statement/prospectus and other relevant materials for the business combination will be mailed to stockholders of Bull Horn and Coeptis as of a record date to be established for voting on the business combination. Stockholders of Bull Horn and Coeptis will also be able to obtain copies of the Registration Statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC's web site at www.sec.gov.
Participants in the Solicitation
Bull Horn, Coeptis and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Bull Horn's and Coeptis' stockholders with respect to the proposed business combination. Investors and securityholders may obtain more detailed information regarding the names and interests in the business combination of the directors and officers of each of Bull Horn and Coeptis such companies' respective filings with the SEC, including the Registration Statement.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Bull Horn and Coeptis with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Bull Horn's and Coeptis' filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Neither Bull Horn nor Coeptis undertake any obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Tiberend Strategic Advisors, Inc.
Investors
Lisa Sher
970-987-2654
lsher@tiberend.com
Media
David Schemelia
609-468-9325
dschemelia@tiberend.com
Bull Horn Holdings Corp.
Edelman
bullhornmedia@edelman.com
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera BiopharmaPress Release | 04/13/2022
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma
PR Newswire
WEXFORD, Pa., April 13, 2022
Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients
WEXFORD, Pa. , April 13, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that the Company has entered into a strategic agreement with Statera Biopharma, Inc. (Nasdaq: STAB) that gives Coeptis the right to acquire Statera's toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently being developed as a treatment for acute radiation syndrome. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency. Coeptis and Statera have agreed to an exclusivity period through the date that is 30 days following the date on which the first draft of the definitive agreement is available to review by both parties.
(PRNewsfoto/Coeptis Therapeutics, Inc.)
Under the terms of the definitive agreement, Coeptis will agree to pay Statera Biopharma six million USD ($6,000,000) and revenue-based milestone payments to be defined in the definitive agreement in exchange for a defined set of purchased assets that include Statera's rights to any product containing entolimod as an active ingredient and all other related TLR5 agonists, related intellectual property, contract rights, inventory and data related to such products.
TLR5 is an innate immunity receptor, which when activated, triggers nuclear factor kappa B (NF-kB) signaling, mobilizing an innate immune response that drives expression of numerous genes, including inhibitors of apoptosis, scavengers of reactive oxygen species, and a spectrum of protective or regenerative cytokines. Entolimod is Statera's most advanced TLR5 agonist technology and is currently in development to treat acute radiation syndrome. Entolimod has also demonstrated preclinical potential in hematology, specifically the treatment of neutropenia and anemia in cancer patients.
"The proposed addition of Statera's TLR5 agonist platform, led by entolimod, a late-stage clinical candidate, offers the potential to significantly enhance our development pipeline and target multiple disease indications that remain underserved by current therapeutic options," said Dave Mehalick, President and Chief Executive Officer of Coeptis Therapeutics. "We are particularly intrigued by the opportunity to advance the development of entolimod for acute radiation syndrome given the current geopolitical climate, which unfortunately elevates the need for medications to address extreme radiation exposure. Moreover, the opportunity to pursue programs in neutropenia and anemia in cancer patients complements Coeptis' mission to improve outcomes for patients with cancer."
About Coeptis Therapeutics
Coeptis Therapeutics, Inc., along with its wholly owned subsidiary Coeptis Pharmaceuticals, Inc. (together "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights is highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. Coeptis was founded in 2017 and is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.
Forward Looking Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from our expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited, to those risks contained in reports filed by us with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in our filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
CONTACT
Tiberend Strategic Advisors, Inc.
Investors
Lisa Sher
lsher@tiberend.com
Media
David Schemelia
dschemelia@tiberend.com$COEP
$COEP Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development
Press Release | 01/20/2022
Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development
Newly formed Scientific Advisory Board includes three members from the prestigious Karolinska Institutet (KI)
PR Newswire
WEXFORD, Pa., Jan. 20, 2022
WEXFORD, Pa., Jan. 20, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announces the formation of its Scientific Advisory Board (SAB), which will contribute key guidance on the advancement of the Company's product portfolio highlighted by CD38-GEAR-NK, a cell therapy technology, and CD38-Diagnostic, an in vitro diagnostic, which the company is co-developing with VyGen-Bio, Inc.
(PRNewsfoto/Coeptis Therapeutics, Inc.)
The Scientific Advisory Board is comprised initially of three renowned scientific researchers from the Karolinska Institutet, Stockholm, Sweden; Evren Alici, M.D., Ph.D.; Hans-Gustaf Ljunggren, M.D., Ph.D; and Arnika Kathleen Wagner, Ph.D.
"The formation of our Scientific Advisory Board and close affiliation with scientists from Karolinska Institutet marks an important milestone in the evolution of Coeptis Therapeutics and our mission to advance cell therapy platforms for cancer," said Dave Mehalick, President and CEO, Coeptis Therapeutics. "Drs. Alici, Ljunggren, and Wagner have been instrumental in the discovery of the GEAR-NK and GEAR Diagnostic platforms, from which our lead products, CD38-GEAR-NK and CD38 Diagnostic, are being developed. We now have the opportunity to benefit directly from their unparalleled knowledge of this technology and its potential to provide a safer and targeted administration of anti-CD38 mAbs in the treatment of CD38-associated cancers."
CD38-GEAR-NK is a natural killer (NK) cell-based investigational therapeutic engineered to enable combination therapy with anti-CD38 mAbs, potentially minimizing the risks and side effects from CD38-positive NK cell fratricide. The first indication is currently expected to be multiple myeloma, an incurable cancer of plasma cells.
CD38-Diagnostic is an investigational in vitro screening tool to potentially pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK.
The members of the new SAB include:
Evren Alici, M.D., Ph.D.
Dr. Alici is the Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital. As a senior researcher and group leader in Hematology at KI, Department of Medicine, he also serves as co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI. Dr. Alici received his M.D. and did his residency at the Ege University, Turkey. He earned his Ph.D. in 2006 at KI.
Dr. Alici's main research interests are novel approaches to generating universal cells including allogeneic NK cells, multiple myeloma, lentiviral and retroviral gene transfer, stem cell transplantation and immunology.
Dr. Alici participated in the planning and design of the first clinical study with gene-modified cells in Sweden and authored the final publication. Additionally, he was also responsible for the first-in-man autologous NK cell therapy clinical trial that was classified as advanced therapy medicinal product use. Dr. Alici is affiliated with VyGen-Bio.
Hans-Gustaf Ljunggren, M.D., PH.D.
Professor Ljunggren is the former Dean of Research at Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital and has functioned as Dean of Research at KI. He is a member of the Nobel Assembly at KI, which awards the Nobel Prize in Physiology or Medicine.
Professor Ljunggren earned his medical and doctoral degrees at KI and also serves as Center Director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI. In 2001, he was appointed Professor of Infection Medicine and Director of the Center for Infectious Medicine (CIM), a Strategic Research Center at the Department of Medicine, and has authored over 300 articles within the fields of immunology, infectious diseases and cancer and been cited more than 40,000 times.
Professor Ljunggren has been a member of the organizing or scientific committees of numerous international conferences and has had multiple national and international assignments, involving external research evaluations and participation in international advisory boards. Dr. Ljunggren is affiliated with VyGen-Bio.
Arnika Kathleen Wagner, Ph.D.
Since 2019, Dr. Wagner has been an assistant professor at the KI's Dept. of Medicine Huddinge, studying NK cells in immunotherapy in Multiple Myeloma. Dr. Wagner is particularly interested in advancing the use of genetically modified NK cells in different immunotherapeutic approaches.
Dr. Wagner earned her M.Sc. in 2008 from the University of Lübeck, Germany and conducted her Ph.D. studies under the supervision of Klas Kärre at the Dept of Microbiology, Tumor and Cell Biology, at KI, where her research focused on NK cells in mouse models for immunotherapy and studied the crosstalk of NK cells with other immune cells. Dr. Wagner is affiliated with VyGen-Bio.
About Coeptis Therapeutics
Coeptis Therapeutics, Inc., along with its wholly owned subsidiary Coeptis Pharmaceuticals, Inc. (together "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights is highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. Coeptis was founded in 2017 and is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.
About Karolinska Institutet
Karolinska Institutet is one of the world's leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country's broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
For more information about Karolinska?Institutet, visit https://ki.se/en/research/research-at-karolinska-institutet
Forward Looking Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from our expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited, to those risks contained in reports filed by us with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in our filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
CONTACT
Tiberend Strategic Advisors, Inc.,
Investors
Lisa Sher
lsher@tiberend.com
Media
David Schemelia
dschemelia@tiberend.com
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-establishes-scientific-advisory-board-to-advance-cell-therapy-product-development-301464646.html
Lucky? Even nodummy did a deep dive on him and his scams.
Haven't looked yet, but I bet the company was dormant and most likely never a SEC registrant and or abandoned shell. We know wade doesn't like a company with a track record or real products.
Why is wade still walking the streets a free man?
Thanks. Looks like the company has been around but we know how Wade scams work.
They changed their name again and sector.
Think they're going to try another stock manipulation play so soon?
Yet another scam. No reverse split yet?
And don't worry, they will be announcing a covid cure soon.
Did the company even exist. Or perhaps even do anything the last 10 years and isn't dormant.
*check the intro page, someone inserted big red letters 2/3rds down inside your area with links to pump page.
Interesting. Have to put my DD cap on.
About Coeptis Therapeutics
Coeptis Therapeutics, Inc. (formerly Vinings Holdings Inc.), along with its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc. (together "Coeptis"), is a pharmaceutical company focused on the development of innovative therapeutics and technologies that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio consists of two clinical-stage drug candidates (CPT1550 and CPT60621), two approved drugs (Conjupri™ (levamlodipine) tablets and Consensi® (amlodipine and celecoxib) tablets), and the product opportunities through Coeptis' two exclusive option agreements with VyGen-Bio, Inc., for co-development rights to a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers which are being developed by VyGen-Bio. Coeptis' business model is designed around maximizing the value of its current product portfolio through in-license agreements, out-license agreements, and co-development relationships, as well as entering into strategic partnerships to expand its product portfolio in new and exciting therapeutic areas such as auto-immune disease and oncology. Coeptis is headquartered in Wexford, PA.
Owner (REGISTRANT) Conjupro Biotherapeutics Inc.
https://tmsearch.uspto.gov/bin/showfield?f=doc&state=4805:tqemkl.2.1
Burke Theraputics
https://burketherapeutics.com/conjupri-tablets
Vinings Holdings Inc., NDYN, changed to Coeptis Therapeutics Inc., COEP:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
$NDYN Coeptis Pharmaceuticals Enters into Exclusive Option Agreements with VyGen-Bio to Co-develop Technologies Designed to Improve the Treatment of CD38-Related Cancers
Press Release | 05/18/2021
Coeptis Pharmaceuticals Enters into Exclusive Option Agreements with VyGen-Bio to Co-develop Technologies Designed to Improve the Treatment of CD38-Related Cancers
Technologies being developed from VyGen-Bio's Gene-Edited Antibody Resistant NK (GEAR-NK) Platform
PR Newswire
WEXFORD, Pa., May 18, 2021
WEXFORD, Pa., May 18, 2021 /PRNewswire/ -- Coeptis Pharmaceuticals, Inc., a wholly-owned subsidiary of Vinings Holdings Inc. (OTC PINK: NDYN), today announced entry into two separate exclusive option agreements with VyGen-Bio, Inc., a majority-owned subsidiary of Vycellix, Inc., involving technologies being studied to potentially improve the treatment of CD38-related cancers. The technologies are CD38-GEAR-NK, a cell therapy product being developed to protect CD38+ natural killer (NK) cells from destruction by anti-CD38 monoclonal antibodies (mAbs), and CD38-Diagnostic, an in vitro diagnostic tool being developed to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. Both technologies are being developed from VyGen-Bio's Gene-Edited Antibody Resistant NK (GEAR-NK) platform, which was discovered by scientists at the Karolinska Institutet in Sweden.
The first option agreement involves co-development rights to CD38-GEAR-NK, which is an autologous, NK cell-based investigational therapeutic derived from a patient's own cells and gene-edited to enable combination therapy with anti-CD38 mAbs, potentially minimizing the risks and side effects from CD38-positive NK cell fratricide. The first indication is expected to be multiple myeloma, an incurable cancer of plasma cells. Per the option agreement, Coeptis has paid VyGen-Bio a non-refundable fee for the exclusive option to purchase the co-development rights to the technology. Coeptis has until December 31, 2021 to exercise the option and pay the specified exercise consideration.
The second option agreement involves co-development rights to CD38-Diagnostic, which is an investigational in vitro screening tool to potentially pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK. Per the option agreement, Coeptis has paid VyGen-Bio a non-refundable fee for the exclusive option to purchase the co-development rights to the technology. Coeptis has until December 31, 2021 to exercise the option and pay the specified exercise consideration.
"At Coeptis, we are focused on identifying and advancing technologies that have the potential to disrupt conventional treatment paradigms and improve patient outcomes," said Dave Mehalick, President and CEO of Coeptis Pharmaceuticals. "The option agreements with VyGen-Bio epitomize this business strategy as each technology may offer the potential to vastly improve the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, by identifying those patients who are most likely to benefit from anti-CD38 mAbs and then potentially 'super charging' a patient's immune system by protecting CD38+ NK cells from destruction by anti-CD38 mAbs."
Mr. Mehalick continued, "We envision these agreements with VyGen-Bio to be an important step in support of our focus in cell and gene therapy."
About Coeptis Pharmaceuticals
Coeptis Pharmaceuticals, Inc., a wholly-owned subsidiary of Vinings Holdings Inc. (OTC PINK: NDYN), is a pharmaceutical company focused on the development of innovative therapeutics and technologies that offer improvements to current therapies thereby improving patient outcomes. Coeptis' product portfolio consists of and two clinical-stage drug candidates – CPT1550 and CPT60621 – and two approved drugs – Conjupri™ (levamlodipine) tablets and Consensi® (amlodipine and celecoxib) tablets. Additionally, Coeptis recently entered into two exclusive option agreements with VyGen-Bio, Inc., Inc. for co-development rights to a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers which are being developed by VyGen-Bio. Coeptis' business model is designed around commercializing and furthering the development of its current product portfolio and maximizing the portfolio's value through in-license agreements, out-license agreements, and co-development relationships, as well as other strategic partnerships in new and exciting therapeutic areas such as auto-immune disease and oncology. Coeptis is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptispharma.com/.
Forward Looking Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited, to those risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
CONTACT
Tiberend Strategic Advisors, Inc.
Investors
Miriam Weber Miller
mmiller@tiberend.com
Media
David Schemelia
dschemelia@tiberend.com
Cision View original content:http://www.prnewswire.com/news-releases/coeptis-pharmaceuticals-enters-into-exclusive-option-agreements-with-vygen-bio-to-co-develop-technologies-designed-to-improve-the-treatment-of-cd38-related-cancers-301293485.html
SOURCE Coeptis Pharmaceuticals, Inc.
This obvious scam must now be higher on the SEC's list.
One down, about six more to go!
Stock is dead and it is by appointment only
Why didn’t the stock trade yesterday? Is there a suspension in the stock?
Lena Pharma is not listed at 1700 Somerset Ave. Looks like a scam address.
Remember Joseph Wade Mezey's wife, Tatania Shishove is a major share holder.
The building looks like one of many past ones claimed by Joseph Wade Mezey to be important/valuable.
https://rehold.com/Windber+PA/SOMERSET+AVE/1700
They just registered with the SEC on 2021-02-19 09:15:39.
https://sec.report/CIK/0001846888
The company was started in 2018. They just updated today, 2/24/2021.
HUGE RED FLAG!
Lisa Pharma, LLC and Lena Pharma are both at the same address. There are no records of an active company besides the names.
ANOTHER BIG RED FLAG.
Hold it and put away for $15-$20+ imo
https://www.nasdaq.com/market-activity/stocks/ndyn/sec-filings
13G filings on 2/19, Lena Pharma LLC & Lisa Pharma LLC
Something is up? Unfortunately, I sold all my shares at the beginning of last week. GLTA!
What is going on here?? I have had this stock since 2010 and wrote it off...wowza!
4.94 ? on very very low volume
boom whats commin hhmm
9K MOVES IT TO 2.50
Joe and Annie are laughing their azzes off.
NDYN $2.00s lets see where we go fun ride 4 sure
Insider enrichment.
All the details of share structure (from 8k) plus the Coeptis shares to be exchanged in the previous post.
I may be wrong but imo, still note a bad share structure
Section 6
(b) Capitalization.
(i) Acquisition Sub. Coeptis Acquisition Corp. has 1,000 shares of commons stock, par value $0.0001 per share, authorized, all of which are issued and outstanding and held by Vinings.
8
(ii) [u]VININGS’s authorized capital stock consists of (A) 750,000,000 shares of common stock, par value $0.0001 per share, 1,708,800 shares of Common Stock are issued and outstanding (2,708,800 common shares outstanding on a fully-diluted basis assuming conversion and exercise of all convertible and exercisable instruments) and (B) 10,000,000 shares of preferred stock, 8,000 shares of which are issued and outstanding as Series B Super Majority Voting Convertible Preferred stock (which such shares of Series B Super Majority Voting Convertible Preferred stock are convertible into 8,000,000 shares of Vinings common stock). All of the issued and outstanding shares of common stock and preferred stock of Vinings were duly and validly issued and fully paid, are non-assessable and free of preemptive rights, and were issued in compliance with all applicable state and federal securities laws.
(iii) Except as shown at Section 6(b) of the Vinings Disclosure Schedule, there are no outstanding (A) options, warrants, or other rights to purchase any capital stock of Vinings or Acquisition Sub; (B) debt securities or instruments convertible into or exchangeable for shares of any capital stock of Vinings or Acquisition Sub; or (C) commitments of any kind for the issuance of additional shares of capital stock or options, warrants or other securities of Vinings or Acquisition Sub.
(iv) Vinings owns all of the outstanding capital stock of Acquisition Sub, free and clear of all liens or other encumbrances.
Add in the Coeptis shares and still a low float:
(b) Effect on Capital Stock.
Conversion of Coeptis Shares. At the Closing, each Coeptis Share issued and outstanding on the Closing Date (as defined in Section 3, below) shall, by virtue of the Merger and without any further action on the part of Coeptis, Vinings, Acquisition Sub, or the holders of the Coeptis Shares as of the Closing Date (the “Original Holders”), be converted into and exchanged for one share of validly issued, fully paid and non-assessable common stock of Vinings (the “Share Ratio”) such that the Original Holders will be issued a total of twenty-five million one hundred and seventy-eight thousand eight hundred and forty (25,178,840) shares of common stock of Vinings (the “Vinings Common Stock”) as a result of the merger, and such shares shall be distributed pro rata to the holders of one hundred percent (100%) of the Coeptis common stock, subject to the receipt of letters of transmittal and any other documents required of the transfer agent; provided that the number of shares of Vinings Common Stock to be issued in connection with the Merger shall be increased on a one-for-one basis for each share of Coeptis Common Stock issued by Coeptis between the Effective Date and the Closing Date (which number of additional shares shall not exceed five million (5,000,000) without Vinings’ consent). All shares of Vinings Common Stock issued upon the exchange of Coeptis Shares in accordance with the terms hereof shall (i) contain a standard restricted securities legend in compliance with the Securities Act and (ii) be deemed to have been issued in full satisfaction of all rights pertaining to such Coeptis Shares. There shall be no further registration of transfers on the stock transfer books of Coeptis of the Coeptis Shares that were outstanding immediately prior to the Closing.
NDYN SECURITY DETAILS
Share Structure
Market Cap Market Cap
514,228
12/31/2020
Authorized Shares
750,000,000
11/30/2020
Outstanding Shares
1,658,800
11/30/2020
Restricted
1,250,400
11/30/2020
Unrestricted
408,400
11/30/2020
Something us definately up. Great close!
NDYN 400% and quite here, lol, must be all insiders buying
yea baby NDYN
yeap good lotto not really sure whats going in here yet
Liking it so far. Looks like 2+ soon
NDYN looking good $2.00 coming this week
NDYN still holding my handful for what ever
Best day so far
New company taking over ?
Followers
|
109
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
11906
|
Created
|
03/04/10
|
Type
|
Free
|
Moderators |
"Coeptis Therapeutics is a biopharmaceutical
company developing innovative cell therapy
platforms for patients with cancer."
OUR MISSION:
"TO IMPROVE OUTCOMES FOR PATIENTS WITH CANCER"
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen;
therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with
CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and
maximize tumor kill via combinatorial approaches otherwise not possible.
Coeptis Therapeutics Holdings, Inc. conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc.
Coeptis Therapeutics Holdings, Inc.
Corporate Headquarters
105 Bradford Road, Suite 420
Wexford, PA 15090
+1 (724) 934-6467
As of March 30, 2023 • 12:02 PM ET
As of March 30, 2023 • 12:02 PM ET
DATE/TIME | SOURCE | NEWS RELEASE |
---|---|---|
03/27/2023 10:47 AM EDT | SeekingAlpha | NBRV, JNCE and ALIM among healthcare movers |
03/27/2023 08:52 AM EDT | SeekingAlpha | IOVA, MQ and ONCS are among pre market gainers |
03/22/2023 08:30 AM EDT | InvestorBrandNetwork | InvestorNewsBreaks - Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal |
06/23/2022 05:27 PM EDT | SeekingAlpha | I-Mab Valuation Offers A Biotech Investment Opportunity |
04/22/2022 03:00 PM EDT | SeekingAlpha | Catalyst watch: Apple earnings, Twitter drama and media eyes on NAB Show |
04/19/2022 01:50 PM EDT | SeekingAlpha | Coeptis Therapeutics to merge with SPAC Bull Horn, uplist to Nasdaq |
04/13/2022 07:48 AM EDT | SeekingAlpha | Statera Biopharma stock soars 31% on potential drug platform acquisition by Coeptis Therapeutics |
05/18/2021 08:53 AM EDT | SeekingAlpha | Coeptis inks exclusive option agreements with VyGen-Bio |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for
information purposes only.
No stock exchange has approved or disapproved of the information here.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |